Quantinno Capital Management LP Grows Stake in argenex SE $ARGX

Quantinno Capital Management LP increased its stake in shares of argenex SE (NASDAQ:ARGX) by 11.1% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 11,148 shares of the company’s stock after purchasing an additional 1,111 shares during the period. Quantinno Capital Management LP’s holdings in argenex were worth $8,141,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. M&T Bank Corp increased its stake in argenex by 20,977.7% during the 4th quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after buying an additional 774,916 shares in the last quarter. Sands Capital Management LLC lifted its position in shares of argenex by 2,046.6% in the fourth quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock valued at $300,110,000 after acquiring an additional 340,245 shares in the last quarter. Invesco Ltd. lifted its position in shares of argenex by 390.4% in the fourth quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock valued at $350,178,000 after acquiring an additional 331,489 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of argenex by 80.1% in the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after acquiring an additional 324,653 shares during the last quarter. Finally, Two Sigma Investments LP boosted its stake in shares of argenex by 570.3% in the third quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after acquiring an additional 250,278 shares during the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Wedbush increased their price objective on argenex from $1,000.00 to $1,050.00 and gave the company an “outperform” rating in a research note on Tuesday, July 28th. Wells Fargo & Company lifted their target price on shares of argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research note on Monday, June 1st. Bank of America upped their target price on shares of argenex from $1,016.00 to $1,088.00 and gave the stock a “buy” rating in a report on Thursday, July 2nd. Royal Bank Of Canada increased their target price on shares of argenex from $945.00 to $1,025.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Finally, Oppenheimer raised their price target on shares of argenex from $1,014.00 to $1,037.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,056.89.

argenex Stock Performance

NASDAQ ARGX opened at $844.50 on Wednesday. The stock’s fifty day moving average is $876.87 and its two-hundred day moving average is $818.24. The firm has a market capitalization of $52.83 billion, a P/E ratio of 32.43, a price-to-earnings-growth ratio of 1.05 and a beta of 0.46. argenex SE has a fifty-two week low of $631.47 and a fifty-two week high of $953.58.

argenex (NASDAQ:ARGX) last issued its earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.86 by $1.46. argenex had a return on equity of 43.59% and a net margin of 32.19%.The company had revenue of $1.54 billion during the quarter, compared to analysts’ expectations of $1.45 billion. As a group, sell-side analysts forecast that argenex SE will post 28.05 EPS for the current year.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.